Literature DB >> 16448135

Marinomycins A-D, antitumor-antibiotics of a new structure class from a marine actinomycete of the recently discovered genus "marinispora".

Hak Cheol Kwon1, Christopher A Kauffman, Paul R Jensen, William Fenical.   

Abstract

Four antitumor-antibiotics of a new structure class, the marinomycins A-D (1-4), were isolated from the saline culture of a new group of marine actinomycetes, for which we have proposed the name "Marinispora". The structures of the marinomycins, which are unusual macrodiolides composed of dimeric 2-hydroxy-6-alkenyl-benzoic acid lactones with conjugated tetraene-pentahydroxy polyketide chains, were assigned by combined spectral and chemical methods. In room light, marinomycin A slowly isomerizes to its geometrical isomers marinomycins B and C. Marinomycins A-D show significant antimicrobial activities against drug resistant bacterial pathogens and demonstrate impressive and selective cancer cell cytotoxicities against six of the eight melanoma cell lines in the National Cancer Institute's 60 cell line panel. The discovery of these new compounds from a new, chemically rich genus further documents that marine actinomycetes are a significant resource for drug discovery.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16448135     DOI: 10.1021/ja0558948

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  64 in total

1.  Chrysophaentins A-H, antibacterial bisdiarylbutene macrocycles that inhibit the bacterial cell division protein FtsZ.

Authors:  Alberto Plaza; Jessica L Keffer; Giuseppe Bifulco; John R Lloyd; Carole A Bewley
Journal:  J Am Chem Soc       Date:  2010-07-07       Impact factor: 15.419

Review 2.  Constructing molecular complexity and diversity: total synthesis of natural products of biological and medicinal importance.

Authors:  K C Nicolaou; Christopher R H Hale; Christian Nilewski; Heraklidia A Ioannidou
Journal:  Chem Soc Rev       Date:  2012-06-28       Impact factor: 54.564

Review 3.  Taxonomy, Physiology, and Natural Products of Actinobacteria.

Authors:  Essaid Ait Barka; Parul Vatsa; Lisa Sanchez; Nathalie Gaveau-Vaillant; Cedric Jacquard; Jan P Meier-Kolthoff; Hans-Peter Klenk; Christophe Clément; Yder Ouhdouch; Gilles P van Wezel
Journal:  Microbiol Mol Biol Rev       Date:  2015-11-25       Impact factor: 11.056

4.  Phylogenetic diversity of gram-positive bacteria cultured from marine sediments.

Authors:  Erin A Gontang; William Fenical; Paul R Jensen
Journal:  Appl Environ Microbiol       Date:  2007-03-30       Impact factor: 4.792

5.  Nitropyrrolins A-E, cytotoxic farnesyl-α-nitropyrroles from a marine-derived bacterium within the actinomycete family Streptomycetaceae.

Authors:  Hak Cheol Kwon; Ana Paula D M Espindola; Jin-Soo Park; Alejandra Prieto-Davó; Mickea Rose; Paul R Jensen; William Fenical
Journal:  J Nat Prod       Date:  2010-11-23       Impact factor: 4.050

Review 6.  Natural products: a continuing source of novel drug leads.

Authors:  Gordon M Cragg; David J Newman
Journal:  Biochim Biophys Acta       Date:  2013-02-18

7.  Seawater requirement for the production of lipoxazolidinones by marine actinomycete strain NPS8920.

Authors:  Michelle J Sunga; Sy Teisan; Ginger Tsueng; Venkat R Macherla; Kin S Lam
Journal:  J Ind Microbiol Biotechnol       Date:  2008-04-04       Impact factor: 3.346

Review 8.  Antitumor compounds from marine actinomycetes.

Authors:  Carlos Olano; Carmen Méndez; José A Salas
Journal:  Mar Drugs       Date:  2009-06-11       Impact factor: 5.118

9.  Activity of the streptogramin antibiotic etamycin against methicillin-resistant Staphylococcus aureus.

Authors:  Nina M Haste; Varahenage R Perera; Katherine N Maloney; Dan N Tran; Paul Jensen; William Fenical; Victor Nizet; Mary E Hensler
Journal:  J Antibiot (Tokyo)       Date:  2010-03-26       Impact factor: 2.649

Review 10.  Novel anti-infective compounds from marine bacteria.

Authors:  Hafizur Rahman; Brian Austin; Wilfrid J Mitchell; Peter C Morris; Derek J Jamieson; David R Adams; Andrew Mearns Spragg; Michael Schweizer
Journal:  Mar Drugs       Date:  2010-03-05       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.